|
|
|
|
|
Antibody-drug conjugates (ADCs)算是一種新興的抗癌療法,結合化療藥物的細胞毒殺作用與抗體辨識tumor-associated antigens (TAAs)的原理,使ADC成為一種快速增長的實體腫瘤藥物療法。在治療實體腫瘤中,除了 EGFR, FGFR, c-MET, 和HER2 等常見的ADC熱門標的外, EpCAM, TROP-2, CD25,等其他新興標的(Table 1)也正在開發中。 |
Sino Biological能提供ADC標靶抗原相關產品,以協助實體腫瘤ADC治療領域的研究。 |
Table 1: ADC target antigens at the preclinical and clinical stages
|
Various categories of ADCs in clinical and preclinical stages
|
ADC target antigens
|
Well-established ADC TAAs
|
HER2, EGFR, EGFRvIII, c-MET, FGFR2, FGFR3
|
ADC TAAs overexpressed on cancer cells
|
EpCAM, BCMA, TROP-2, AXL, HER3, CD166, CEACAM5, GPNMB, Mesothelin, CD70
|
Target antigens in TME
|
CD25/IL2R, B7-H3, ANTXR1
|
Target antigens in CSCs
|
PTK7, ROR1, 5T4
|
|
|
|
|
Sino Biological提供ADC 治療領域相關高品質產品,產品經活性驗證,也被引用至多篇國際熱門期刊並受到認可。 |
更多資訊 !
|
|
ADC 療法相關重組蛋白產品特色
|
|
High-Purity
|
HPLC-Verified
|
High-Acitivity
|
Cited by Researchers
|
|
|
|
Human EGFR Protein
(Cat#: 10001-H27H-B)
|
Human CD25/IL2R alpha Protein
(Cat#: 10165-H08H)
|
|
|
Immobilized Human EGF (Cat#: 10605-H01H) can bind Human EGFR
|
Ability to inhibit IL2-induced proliferation of M07e cells
|
|
Human c-MET Protein
(Cat#: 10692-H08H)
|
Human BCMA Protein
(Cat#: 10620-H08H)
|
|
|
Immobilized Cynomolgus HGF (Cat#: 90286-CNAH) can bind Human c-MET
|
Immobilized Human BAFF (Cat#: 10056-H01H) can bind Human BCMA
|
|
|
更多資訊
|
其它相關蛋白
|
|
|
|
|